Advertisement

Hormones

, Volume 18, Issue 1, pp 107–108 | Cite as

Metabolic syndrome: joint diagnostic criteria and links with comorbidities

  • Niki KatsikiEmail author
  • Michael Doumas
  • Vasilios Athyros
Letter to the Editor

Notes

Compliance with ethical standards

Conflict of interest

NK has given talks, attended conferences, and participated in trials sponsored by Amgen, Angelini, Astra Zeneca, Boehringer Ingelheim, Galenica, MSD, Novartis, Novo Nordisk, Sanofi, and WinMedica. MD has nothing to declare. VA has given talks, attended conferences, and participated in trials sponsored by MSD, Angelini, Sanofi, and Amgen.

References

  1. 1.
    Zafar U, Khaliq S, Ahmad HU, Manzoor S, Lone KP (2018) Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links. Hormones (Athens) 17(3):299–313Google Scholar
  2. 2.
    Alberti KG, Eckel RH, Grundy SM et al (2009) International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1652CrossRefGoogle Scholar
  3. 3.
    Diabetes Canada Clinical Practice Guidelines Expert Committee, Punthakee Z, Goldenberg R, Katz P (2018) Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 42(Suppl 1):S10–S15Google Scholar
  4. 4.
    Athyros VG, Ganotakis ES, Tziomalos K et al (2010) Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin 26:713–719CrossRefGoogle Scholar
  5. 5.
    Katsiki N, Athyros VG, Mikhailidis DP (2015) Metabolic syndrome: different definitions and gender-specific associations with cardiovascular risk factors. Diab Vasc Dis Res 12:471–472CrossRefGoogle Scholar
  6. 6.
    Athyros VG, Ganotakis E, Kolovou GD, et al (2011) Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT) collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 9: 647–657Google Scholar
  7. 7.
    Grundy SM, Cleeman JI, Daniels SR et al (2005) American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112:2735–2752CrossRefGoogle Scholar
  8. 8.
    Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A (2018) Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol 16:219–227CrossRefGoogle Scholar
  9. 9.
    Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP (2015) Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol 21:6820–6834CrossRefGoogle Scholar
  10. 10.
    Athyros VG, Alexandrides TK, Bilianou H et al (2017) The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism 71:17–32CrossRefGoogle Scholar
  11. 11.
    Katsiki N, Mikhailidis DP (2018) Abnormal peri-organ or intra-organ fat deposition and vascular risk. Angiology 2018;69(10):841–842Google Scholar
  12. 12.
    Katsiki N, Athyros VG, Mikhailidis DP (2016) Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk? Curr Vasc Pharmacol 14:432–441CrossRefGoogle Scholar
  13. 13.
    Katsiki N, Mikhailidis DP, Wierzbicki AS (2013) Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol 28:458–463CrossRefGoogle Scholar
  14. 14.
    Fitzgibbons TP, Czech MP (2014) Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J Am Heart Assoc 3:e000582CrossRefGoogle Scholar
  15. 15.
    Katsiki N, Mikhailidis DP, Mantzoros C (2018) Non-alcoholic fatty liver disease and colorectal cancer: a marker of risk or common causation? Metabolism 2018;87:A10–A13Google Scholar
  16. 16.
    Esposito K, Capuano A, Giugliano D (2014) Metabolic syndrome and cancer: holistic or reductionist? Endocrine 45:362–364CrossRefGoogle Scholar
  17. 17.
    Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE (2017) Nonalcoholic fatty liver disease: evolving paradigms. World J Gastroenterol 23:6571–6592CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2018

Authors and Affiliations

  • Niki Katsiki
    • 1
    Email author
  • Michael Doumas
    • 1
  • Vasilios Athyros
    • 1
  1. 1.Second Propedeutic Clinic of Internal MedicineAristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations